Jan 28, 2021
ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology
Jan 07, 2021
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Oct 14, 2019
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
Sep 25, 2019
ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going "Base Line/On Therapy" (BOT) Phase II Clinical Trial
Sep 04, 2019
ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019
Jun 20, 2019
ImaginAb to Present at SNMMI 2019 Annual Meeting
May 30, 2019
ImaginAb to Present at Upcoming Investor and Scientific Conferences in May and June 2019
Feb 26, 2019
ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board
Jan 18, 2019
ImaginAb Enrolls First Patient in Phase II Clinical Trial
Jan 03, 2019
ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics
Jan 02, 2019
ImaginAb Announces Strengthening of Board and Executive Leadership Team
Oct 08, 2018
ImaginAb Announces Collaboration with Merck for CD8 T cell I/O Imaging Agent
Aug 29, 2018
ImaginAb and CPDC Announce Clinical Trial Supply Manufacture and Distribution Agreement for ImaginAb's CD8 Immuno PET Tracer
Jun 22, 2018
ImaginAb Reconstitutes Japanese Subsidiary
May 17, 2018
ImaginAb Reconstitutes Scientific Advisory Board